肩关节置换术前皮质类固醇注射时机与翻修风险的关系
本研究基于2006年1月至2017年12月的全国保险数据库,纳入4252例接受全肩关节置换术(TSA)或反式肩关节置换术(rTSA)的患者,分析术前一年内皮质类固醇注射时机与翻修及假体周围感染(PJI)风险的关系,发现注射后3个月内手术显著增加翻修风险,其他时间间隔无显著增加。
要点
- 术前3个月内接受皮质类固醇注射者翻修风险显著增加(OR 2.61,95%CI 1.77-3.28,p<0.001)。
- 其他时间间隔(3-6、6-9、9-12个月)翻修风险无显著增加。
- Charlson合并症指数≥3是全因翻修的显著独立危险因素(OR 4.00,95%CI 1.40-8.92,p=0.036)。
核心结论
- 术前皮质类固醇注射时机与TSA或rTSA后全因翻修发生率存在时间依赖关系。
- 作者认为,皮质类固醇注射与TSA或rTSA之间应至少间隔3个月,以降低后续翻修手术风险。
研究设计与样本
- 回顾性队列研究,数据来自2006年1月至2017年12月的全国保险数据库。
- 纳入术前一年内接受同侧肩关节皮质类固醇注射并随后行TSA或rTSA的患者,按注射至手术时间分为<3个月、3-6个月、6-9个月、9-12个月四组,并与术前一年内未注射的对照组比较。
- 共纳入4252例患者,其中1632例(38.4%)术前一年内接受注射,2620例(61.6%)未接受。
- 采用单因素和多因素分析评估时间间隔与结局的关联。
主要发现
- 多因素分析显示,与对照组相比,术前<3个月接受注射者翻修风险显著增加(OR 2.61,95%CI 1.77-3.28,p<0.001)。
- 其他时间间隔组翻修风险均无显著增加。
- Charlson合并症指数≥3是全因翻修的显著独立危险因素(OR 4.00,95%CI 1.40-8.92,p=0.036)。
临床怎么用
- 作者认为,皮质类固醇注射与TSA或rTSA之间应至少间隔3个月以降低翻修风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Corticosteroid injections are often used to manage glenohumeral arthritis in patients who may be candidates for future total shoulder arthroplasty (TSA) or reverse shoulder arthroplasty (rTSA). In the conservative management of these patients, corticosteroid injections are often provided for symptomatic relief. The purpose of this study was to determine if the timing of corticosteroid injections prior to TSA or rTSA is associated with changes in rates of revision and periprosthetic joint infection (PJI) following these procedures. METHODS: Data were collected from a national insurance database from January 2006 to December 2017. Patients who underwent shoulder corticosteroid injection within one year prior to ipsilateral TSA or rTSA were identified and stratified into the following cohorts: < three months, three to six months, six to nine months, and nine to 12 months from time of corticosteroid injection to TSA or rTSA. A control cohort with no corticosteroid injection within one year prior to TSA or rTSA was used for comparison. Univariate and multivariate analyses were conducted to determine the association between specific time intervals and outcomes. RESULTS: In total, 4,252 patients were included in this study. Among those, 1,632 patients (38.4%) received corticosteroid injection(s) within one year prior to TSA or rTSA and 2,620 patients (61.6%) did not. On multivariate analysis, patients who received corticosteroid injection < three months prior to TSA or rTSA were at significantly increased risk for revision (odds ratio (OR) 2.61 (95% confidence interval (CI) 1.77 to 3.28); p < 0.001) when compared with the control cohort. However, there was no significant increase in revision risk for all other timing interval cohorts. Notably, Charlson Comorbidity Index ≥ 3 was a significant independent risk factor for all-cause revision (OR 4.00 (95% CI 1.40 to 8.92); p = 0.036). CONCLUSION: There is a time-dependent relationship between the preoperative timing of corticosteroid injection and the incidence of all-cause revision surgery following TSA or rTSA. This analysis suggests that an interval of at least three months should be maintained between corticosteroid injection and TSA or rTSA to minimize risks of subsequent revision surgery. Cite this article: Bone Joint J 2022;104-B(5):620-626.
引用
- Stadecker M, Gu A, Ramamurti P, et al. Risk of revision based on timing of corticosteroid injection prior to shoulder arthroplasty. Bone Joint J. 2022. PMID: 35491573. doi:10.1302/0301-620X.104B5.BJJ-2021-0024.R3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。